Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03657342 · ClinicalTrials.gov registry record · Phase 3
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)
A Phase 3 study, sponsored by Zambon SpA.
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT03657342 is a Phase 3 study that has completed, run by Zambon SpA. The registered enrollment target is 62 participants.
The verdict
NCT03657342, a Phase 3 study, has completed, sponsored by Zambon SpA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
The objective of this trial is to assess the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) as add-on therapy to standard of care (SoC) as compared to SoC alone in single lung transplant recipients with chronic lung allograft dysfunction (CLAD)-bronchiolitis obliterans syndrome (BOS).
Interventions
- DRUG Liposomal Cyclosporine A
- DRUG standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2024-04-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03657342
The ClinicalTrials.gov registry entry for NCT03657342 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zambon SpA, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal Cyclosporine A is the first listed.
NCT03657342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03657342 about?
NCT03657342 is a clinical study titled "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)". The objective of this trial is to assess the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) as add-on therapy to standard of care (SoC) as compared to SoC alone in single lung transplant recipients with chronic lung allograft dysfunction (CLAD)-bronchiolitis obliterans syndrome ...
What is the current status of trial NCT03657342?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2019-03-26. Estimated completion is 2024-04-16.
What interventions are being tested in trial NCT03657342?
The interventions under investigation include: Liposomal Cyclosporine A (DRUG), standard of care (DRUG).
Who is sponsoring clinical trial NCT03657342?
This trial is sponsored by Zambon SpA, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.